Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shingo Nakayamada

Showing results (21-30 of 227) with videos related to

Pageof 23
Sort By:
Current Drug Targets. Inflammation and Allergy|August 17, 2005
Osteoblasts and osteoclasts in bone remodeling and inflammationYoshiya Tanaka, Shingo Nakayamada, Yosuke Okada
RMD Open|December 31, 2024
Fine-tuning SLE treatment: the potential of selective TYK2 inhibitionYurie Satoh-Kanda, Shingo Nakayamada, Yoshiya Tanaka
Critical Reviews in Immunology|April 20, 2019
Regulatory Mechanism of The Induction of Regulatory T Cells through Growth Factors Released by Human Mesenchymal Stem CellsIppei Miyagawa, Shingo Nakayamada, Masahiro Kondo, et al.
Arthritis Research & Therapy|March 2, 2022
Preferable outcome of Janus kinase inhibitors for a group of difficult-to-treat rheumatoid arthritis patients: from the FIRST RegistrySae Ochi, Koshiro Sonomoto, Shingo Nakayamada, et al.
Expert Opinion on Pharmacotherapy|October 4, 2016
Chemical JAK inhibitors for the treatment of rheumatoid arthritisShingo Nakayamada, Satoshi Kubo, Shigeru Iwata, et al.
Rheumatology (Oxford, England)|November 30, 2020
Safety and efficacy of fostamatinib in rheumatoid arthritis patients with an inadequate response to methotrexate in phase II OSKIRA-ASIA-1 and OSKIRA-ASIA-1X studyYoshiya Tanaka, David Millson, Shigeru Iwata, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|September 1, 2016
Recent Progress in JAK Inhibitors for the Treatment of Rheumatoid ArthritisShingo Nakayamada, Satoshi Kubo, Shigeru Iwata, et al.
Modern Rheumatology|October 10, 2006
Human urinary trypsin inhibitor bolus infusion improved severe interstitial pneumonia in mixed connective tissue diseaseShizuyo Tsujimura, Kazuyoshi Saito, Shingo Nakayamada, et al.
Rheumatology (Oxford, England)|December 26, 2022
Evaluation of asymptomatic cerebral ischemia by arterial spin-labeling magnetic resonance imaging of the brain in Takayasu arteritisKatsuhide Kusaka, Shingo Nakayamada, Shigeru Iwata, et al.
The Journal of Rheumatology|January 6, 2004
Etidronate prevents high dose glucocorticoid induced bone loss in premenopausal individuals with systemic autoimmune diseasesShingo Nakayamada, Yosuke Okada, Kazuyoshi Saito, et al.
Pageof 23

Showing results (21-30 of 227) with videos related to

Sort By:
Pageof 23
Current Drug Targets. Inflammation and Allergy|August 17, 2005
Osteoblasts and osteoclasts in bone remodeling and inflammationYoshiya Tanaka, Shingo Nakayamada, Yosuke Okada
RMD Open|December 31, 2024
Fine-tuning SLE treatment: the potential of selective TYK2 inhibitionYurie Satoh-Kanda, Shingo Nakayamada, Yoshiya Tanaka
Critical Reviews in Immunology|April 20, 2019
Regulatory Mechanism of The Induction of Regulatory T Cells through Growth Factors Released by Human Mesenchymal Stem CellsIppei Miyagawa, Shingo Nakayamada, Masahiro Kondo, et al.
Arthritis Research & Therapy|March 2, 2022
Preferable outcome of Janus kinase inhibitors for a group of difficult-to-treat rheumatoid arthritis patients: from the FIRST RegistrySae Ochi, Koshiro Sonomoto, Shingo Nakayamada, et al.
Expert Opinion on Pharmacotherapy|October 4, 2016
Chemical JAK inhibitors for the treatment of rheumatoid arthritisShingo Nakayamada, Satoshi Kubo, Shigeru Iwata, et al.
Rheumatology (Oxford, England)|November 30, 2020
Safety and efficacy of fostamatinib in rheumatoid arthritis patients with an inadequate response to methotrexate in phase II OSKIRA-ASIA-1 and OSKIRA-ASIA-1X studyYoshiya Tanaka, David Millson, Shigeru Iwata, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|September 1, 2016
Recent Progress in JAK Inhibitors for the Treatment of Rheumatoid ArthritisShingo Nakayamada, Satoshi Kubo, Shigeru Iwata, et al.
Modern Rheumatology|October 10, 2006
Human urinary trypsin inhibitor bolus infusion improved severe interstitial pneumonia in mixed connective tissue diseaseShizuyo Tsujimura, Kazuyoshi Saito, Shingo Nakayamada, et al.
Rheumatology (Oxford, England)|December 26, 2022
Evaluation of asymptomatic cerebral ischemia by arterial spin-labeling magnetic resonance imaging of the brain in Takayasu arteritisKatsuhide Kusaka, Shingo Nakayamada, Shigeru Iwata, et al.
The Journal of Rheumatology|January 6, 2004
Etidronate prevents high dose glucocorticoid induced bone loss in premenopausal individuals with systemic autoimmune diseasesShingo Nakayamada, Yosuke Okada, Kazuyoshi Saito, et al.
Pageof 23